Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Danavorexton in Idiopathic Hypersomnia
NCT04091438Phase 1Completed
- Sponsor
- Millennium Pharmaceuticals
- Start
- Jan 2020
- Primary completion
- Nov 2020
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial of danavorexton in idiopathic hypersomnia (IH) (2 arms), sponsored by Millennium Pharmaceuticals. Primary endpoints: Percentage of Participants Who Experienced at Least One Treatment-emergent Adverse Event, Percentage of Participants With Markedly Abnormal Criteria for Clinical Safety Laboratory Tests and 2 more. Started Jan 2020; status: completed.
02
Drugs
danavorexton
03
Conditions
idiopathic hypersomnia (IH)
Beyond the preview
Go deeper on NCT04091438.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04091438.